0000000000126233

AUTHOR

David A. Krantz

showing 1 related works from this author

First-trimester screening for trisomy-21 using a simplified method to assess the presence or absence of the fetal nasal bone.

2005

Objective To determine the benefit of including nasal bone assessment in addition to standard first-trimester markers (nuchal translucency, free beta human chorionic gonadotropin and pregnancy-associated plasma protein A) as a screening test for Down syndrome, using a strict criterion for classification of nasal bone absence. Study design Nasal bone assessment was conducted in 2411 patients with crown-rump length between 45 and 84 mm, including 15 patients with Down syndrome. A patient was considered to have an absent nasal bone only if there was no evidence of present nasal bone. Unlike other studies, nasal bone was classified as present when there was evidence of a thin echogenic line und…

AdultDown syndromemedicine.medical_specialtyPregnancy-associated plasma protein AUrologyAneuploidyPrenatal diagnosisEmbryonic StructuresSensitivity and SpecificityCrown-Rump LengthUltrasonography PrenatalPredictive Value of TestsPregnancyReference ValuesRisk FactorsmedicineConfidence IntervalsHumansMass ScreeningNasal BoneProbabilityObstetricsbusiness.industryObstetrics and GynecologyEchogenicityPrenatal Caremedicine.diseaseNasal boneConfidence intervalPregnancy Trimester FirstCase-Control StudiesLinear ModelsFemaleDown SyndromeTrisomybusinessNuchal Translucency MeasurementAmerican journal of obstetrics and gynecology
researchProduct